Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS
17 janv. 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company...
FDA’s Peter Marks, M.D., Ph.D. to deliver Keynote Address at 2023 Muscular Dystrophy Association Clinical & Scientific Conference
10 janv. 2023 06h00 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific...
Muscular Dystrophy Association Elects Governor Brad Henry as Chairman and Christopher Rosa, Ph.D. as Vice Chairman of the Board of Directors
09 janv. 2023 09h20 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the election of new Board of Directors leadership. Governor Brad Henry will now serve as...
Eledon Pharmaceuticals Provides Business and Pipeline Updates
09 janv. 2023 08h31 HE
|
Eledon Pharmaceuticals, Inc.
Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Continued enrollment in open-label Phase 1b kidney transplant trial with initial data...
Athira Pharma Provides 2023 Pipeline Outlook
05 janv. 2023 07h00 HE
|
Athira Pharma, Inc.
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase...
Le masitinib reçoit la désignation de médicament orphelin pour le traitement de la sclérose latérale amyotrophique en Suisse
27 déc. 2022 13h04 HE
|
AB Science
COMMUNIQUE DE PRESSE LE MASITINIB REÇOIT LA DÉSIGNATION DE MÉDICAMENT ORPHELIN POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) EN SUISSE Paris, 26 décembre 2022, 19h AB Science SA...
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
27 déc. 2022 13h04 HE
|
AB Science
PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm CET AB Science SA (Euronext - FR0010557264...
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
21 déc. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion...
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
05 déc. 2022 07h30 HE
|
Athira Pharma, Inc.
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS Data adds to the growing body of evidence...
Major investment in top talent in ALS research
24 nov. 2022 09h00 HE
|
ALS Society of Canada
Toronto, ON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are powering innovative discoveries and treatments for amyotrophic lateral sclerosis (ALS)...